Date: 2016-05-10
Type of information: R&D agreement
Compound: small molecule modulators of an undisclosed G-protein coupled receptor
Company: Axxam (Italy) MD Anderson Cancer Center (USA - TX)
Therapeutic area: Neurodegenerative diseases
Type agreement: R&D
Action mechanism: GPCR modulator
Disease: Alzheimer's disease
Details: * On December 4, 2015, Axxam announced that it has entered into a research collaboration with the Neurodegeneration Consortium (NDC) at The University of Texas MD Anderson Cancer Center (MD Anderson). The aim of the collaboration is to identify and develop novel small molecule modulators of an undisclosed G-protein coupled receptor linked to Alzheimer’s disease. This collaboration is the latest addition to a multi-year relationship between Axxam and MD Anderson and builds on Axxam’s expertise in the development of robust functional assays for membrane proteins, its screening platform, the access to Axxam’s compound collection AXXDIV2.0 and the significant experience at both Axxam and MD Anderson of integrated neuroscience drug discovery.
Financial terms:
Latest news:
